Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of LY03017 in Healthy Adults
NCT06980207Phase 1Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD), Parkinson's disease (PD) and schizophrenia comparing LY03017 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Planned start May 2025; status: not yet recruiting.
02
Drugs
LY03017
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)schizophrenia
Beyond the preview
Go deeper on NCT06980207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980207.